Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Spring Bank (SBPH) Stops Dosing In HBV Studies, Stock Down

By Zacks Investment ResearchStock MarketsDec 26, 2019 09:04PM ET
www.investing.com/analysis/spring-bank-sbph-stops-dosing-in-hbv-studies-stock-down-200495156
Spring Bank (SBPH) Stops Dosing In HBV Studies, Stock Down
By Zacks Investment Research   |  Dec 26, 2019 09:04PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Shares of clinical-stage biopharmaceutical company Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) plummeted 66.8% after it stopped dosing and enrolling patients in its mid-stage studies on lead product candidate, inarigivir.

The phase IIb CATALYST studies are evaluating inarigivir soproxil 400mg for the treatment of chronic hepatitis B virus (HBV). The candidate is designed to activate within hepatic cells retinoic acid-inducible gene 1 (RIG-I), which has been shown to inhibit HBV viral replication and induce the intracellular interferon signaling pathways for antiviral defense.

However, the company decided to stop the dosing of inarigivir 400mg in the CATALYST studies after observing clinical findings from the CATALYST 2 study of virally-suppressed chronic HBV patients. Three subjects participating in this study showed evidence of hepatocellular dysfunction and an elevation of alanine transaminase (ALT), potentially consistent with liver injury rather than immune flares. Spring Bank is evaluating and analyzing the data. The company is further evaluating safety data across almost 100 patients who have received inarigivir at this dose.

Additionally, the company has stopped dosing and enrollment in all other studies of inarigivir in subjects with chronic HBV.

The news disappointed investors as inarigivir is the company’s lead candidate and the successful development of the same would have boosted its growth prospects. Spring Bank’s stock has plunged 88.5% in the year so far compared with the industry's growth of 10.3%.

We note that the company has entered into a clinical trial supply and collaboration agreement with Gilead Sciences, Inc. (NASDAQ:GILD) that has been subsequently amended. Per the deal, Gilead is funding and conducting a phase II study evaluating inarigivir (50mg, 200mg and 400mg) co-administered with Vemlidy 25 mg (tenofovir alafenamide) in patients infected with chronic HBV. Interim top-line results were positive.

Other FDA-approved treatments for patients with chronic HBV include Bristol-Myers Squibb Company’s (NYSE:BMY) Baraclude. In October, Arbutus Biopharma Corporation (NASDAQ:ABUS) discontinued the clinical development of AB-506, an oral capsid inhibitor for the treatment of chronic hepatitis B.

Apart from inarigivir, Spring Bank is developing its lead STING agonist product candidate, SB 11285, an immunotherapeutic agent for the treatment of selected cancers.

Spring Bank currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>



Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report

Gilead Sciences, Inc. (GILD): Free Stock Analysis Report

Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report

Spring Bank Pharmaceuticals, Inc. (SBPH): Free Stock Analysis Report

Original post
Spring Bank (SBPH) Stops Dosing In HBV Studies, Stock Down
 

Related Articles

Spring Bank (SBPH) Stops Dosing In HBV Studies, Stock Down

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email